Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 94
- Registration Number
- NCT01038635
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01039155
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT01016600
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 98
- Registration Number
- NCT01015352
- Locations
- 🇫🇷
Hôpital Brabois, Nancy, France
🇫🇷Hôpital Avignon, Avignon, France
🇫🇷Hôpital Archet1, Nice, France
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01011283
- Locations
- 🇺🇸
Stanford University Cancer Center, Stanford, California, United States
🇺🇸Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 14
- Registration Number
- NCT01004991
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 7
- Registration Number
- NCT00997243
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT00948064
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
- Conditions
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT00946647
- Locations
- 🇺🇸
Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States
🇺🇸Goshen Center for Cancer Care IU Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Kansas Hospital and Medical Center SC - Univ KS, Kansas City, Kansas, United States
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00934440
- Locations
- 🇺🇸
Stormont-Vail Cotton O'Neil Cancer Center, Topeka, Kansas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.